research use only

Deutivacaftor (VX-561, Ivacaftor-D9) CFTR Modulator

Name: Deutivacaftor (VX-561, Ivacaftor-D9)
Brand: Selleck Chemicals
SKU: E1743
Rating: 5 (1 reviews)

Cat.No.: E1743

VX-561 (CTP-656) is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells.

Chemical Structure

Molecular Weight: 401.55

Jump to

Quality Control

Batch: E174301 DMSO]80 mg/mL]false]Ethanol]4 mg/mL]false]Water]Insoluble]false Purity: 99.56%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS
Datasheet

99.56

Related Targets	CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase GluR
Other CFTR Inhibitors	Tezacaftor (VX-661) VX-445 (Elexacaftor) Vanzacaftor (VX-121) CFTRinh-172 GLPG1837 Galicaftor (ABBV-2222) GlyH-101 FDL169 IOWH032 PPQ-102

Chemical Information, Storage & Stability

Molecular Weight	401.55	Formula	C₂₄H₁₉D₉N₂O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1413431-07-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Solubility

In vitro
Batch:

DMSO : 80 mg/mL (199.22 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 4 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.000mg/ml (9.96mM)	Taking the 1 mL working solution as an example, add 50 μL of 80 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.650mg/ml (1.62mM)	Taking the 1 mL working solution as an example, add 50 μL of 13 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	CFTR 255 nM(EC50)
References	[1] https://pubmed.ncbi.nlm.nih.gov/28611092/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-28)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05422222	ACTIVE_NOT_RECRUITING	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	2022-06-21	PHASE3
NCT05844449	ENROLLING_BY_INVITATION	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	2023-08-11	PHASE3
NCT06154447	COMPLETED	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	2023-12-12	PHASE1
NCT07349394	COMPLETED	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	2026-01-12	PHASE1
NCT06299709	COMPLETED	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	2024-03-13	PHASE1
NCT06299696	COMPLETED	Cystic Fibrosis	Vertex Pharmaceuticals Incorporated	2024-03-26	PHASE1

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):